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γ-Secretase is an enzyme complex that 
mediates both Notch signaling and β -
amyloid precursor protein (APP) 
processing, resulting in the generation of 
Notch intracellular domain (NICD), APP 
intracellular domain (AICD) and the 
amyloid β-peptide (Aβ), the latter playing a 
central role in Alzheimer’s disease (AD). By 
a hitherto undefined mechanism, the 
activity of γ -secretase gives rise to Aβ  
peptides of different lengths, where Aβ42 is 
considered to play a particular role in AD. 
In this study we have examined the role of 
the large hydrophilic loop (amino acids 320-
374, encoded by exon 10) of presenilin 1 
(PS1), the catalytic subunit of γ -secretase, 
for γ -secretase complex formation and 
activity on Notch and APP processing. 
Deletion of exon 10 resulted in impaired PS1 
endoproteolysis, γ -secretase complex 
formation and had a differential effect on 
Aβ-peptide production. While the 
production of Aβ38, Aβ39 and Aβ40 was 
severely impaired, the effect on Aβ42 was 
affected to a lesser extent, implying that the 
production of the AD-related Aβ42 peptide 
is separate from the production of the Aβ38, 
Aβ39 and Aβ40 peptides. Interestingly, 
formation of the intracellular domains of 
both APP (AICD) and Notch (NICD) was 
intact, implying a differential cleavage 
activity between the epsilon/S3 and gamma-
sites. The most C-terminal amino acids of 
the hydrophilic loop were important for 
regulating APP processing. In summary, the 
large hydrophilic loop of PS1 appears to 
differentially regulate the relative 
production of different Aβ peptides without 
affecting Notch processing, two parameters 
of significance when considering γ -secretase 
as a target for pharmaceutical intervention 
in AD. 
Alzheimer’s disease (AD) is the most 
common form of dementia in elderly and is a 
multifactorial disease caused by a progressive 
neurodegeneration, leading to dementia and 
eventually to death. Neuropathological 
hallmarks of AD include intracellular 
neurofibrillary tangles composed of the 
hyperphosphorylated tau protein and 
extracellular senile plaques, which are mainly 
deposits of the amyloid β -peptide (Aβ) (1,2). 
Aβ is generated from the amyloid precursor 
protein (APP) by a sequential cleavage of β -
secretase (BACE) and γ -secretase (3). 
Interfering with either β - or γ -secretase 
activities hold great promise as disease-
modifying strategies for AD.  
γ-Secretase is a member of a subset of 
proteases that cleaves its substrate within the 
membrane, a process that has been named 
regulated intramembrane proteolysis (RIP) (4). 
In contrast to other enzymes catalyzing RIP, γ-
secretase is a multi-subunit complex composed 
of four members; presenilin (PS), nicastrin, 
Pen-2 and Aph-1 (5-8). PS1 plays a central 
role in the complex since it provides the 
catalytic core of the complex via Asp-257 and 
Asp-385, located in transmembrane domains 
(TMD) 6 and 7, respectively (7). Apart from 
APP, γ -secretase is also involved in the 
processing of many other types of Type I 
transmembrane proteins, most importantly the 
Notch receptor. Notch is an important 
signaling molecule in cell differentiation 
during development but recent studies in adult 
mice using non-selective γ -secretase inhibitors 
have revealed its importance during adulthood 
as well. Perturbations of Notch signaling in 
adult mice affect cell homeostasis, tissue 
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differentiation in lymphocytes, gastrointestinal 
tracts, pancreas and the skin (9-12).  
There are two homologues of PS in 
humans, PS1 and PS2, which have been 
characterized as nine TMD proteins (13-15) 
and share an average homology of 63%, and 
up to 95% within the TMDs (reviewed in 
(16)). The PS molecules undergo 
endoproteolysis upon assembly of all γ -
secretase members in the ER and/or early 
Golgi compartment, generating the active N-
terminal and C-terminal fragment (NTF and 
CTF) (17). The Aβ-peptide produced from γ -
secretase-mediated cleavage of APP can be of 
various lengths, 37-43 amino acids, where the 
most abundant forms are Aβ40 and Aβ42 (18-
20). The Aβ42 peptide is more prone to 
aggregate and believed to be the toxic form 
that causes synaptic and neuronal damage in 
the brain (21). Many studies have recently 
pointed out the ratio between these C-terminal 
variants to be of importance for the formation 
of plaques. For instance many familial 
Alzheimer’s disease mutations (FAD) in PS1 
and 2 cause an increase in Aβ42/Aβ40 ratio 
either by decreasing the production of Aβ40 or 
by increasing the Aβ42 generation (22,23). 
This increased ratio is often considered as gain 
of function of the γ-secretase complex. 
However, most of the FAD PS mutants have 
reduced proteolytic activity implying that the 
mutations are instead loss of function 
mutations (22-25). Although PS1 and PS2 
share a high degree of homology and can form 
γ-secretase complexes that are both active on 
APP and Notch processing, there are some 
domains that differ extensively between these 
two proteins, especially the large cytoplasmic 
loop between TMD 6 and 7 (26). These loops 
are 110 amino acids in length in PS1 and 84 
amino acids in length in PS2 and share only 
16% homology when performing protein blast 
alignment (www.blast.nvbi.nlm.nih.gov). It 
has been shown that the PS1 loop binds to β -
catenin and N-cadherin but it has been 
demonstrated that the β -catenin binding 
domain is not essential for γ -secretase activity 
since a PS1 molecule lacking the loop can 
rescue a PS1 -/- lethal phenotype (27). 
Moreover, the absence of the large cytoplasmic 
loop does not influence the increased 
Aβ42/Aβ40 ratio caused by PS1 and PS2 FAD 
mutations (28). Recently, however, Deng et al. 
showed that PS1∆exon 10 knock-in mice, 
which lacks a big portion of the large 
cytoplasmic loop, had increased amyloid 
pathology and impaired γ -secretase activity 
(assessed by accumulation of APP-CTF and 
reduced Aβ40 formation) (29), indicating a 
more pronounced functional role for this large 
domain.  
In order to further probe the functional 
role of the large cytoplasmic loop in PS1, we 
have investigated this region systematically in 
cells devoid of both PS1 and PS2.  
 
EXPERIMENTAL PROCEDURES 
 
cDNA constructs- Full-length PS1wt were 
cloned into the pcDNA5FRT/TO vector 
(Invitrogen) on BamH1/Not1 sites. The 
PS1∆exon 10 construct lacks the amino acids 
320-374 (PS1 numbering) and was first created 
by using PCR with the BGH primer and the 
∆exon 10 Fw primer and the T7 and ∆exon 10 
Rev primers (Supplementary Data, Table S1), 
respectively. After a second PCR, the two 
fragments were linked together using the T7 
and BGH primers and the PS1∆exon 10 
molecule was cloned into the pcDNAFRT/TO 
vector on BamH1/Not1 sites. PS1 NTFwt and 
CTFwt have been described elsewhere (30). 
The PS1 CTF N-terminal truncated constructs 
were created by in vitro mutagenesis according 
to Quick Change mutagenesis protocol 
(Stratagene) using following primers: CTFcasp 
(start 345), CTF start 355, CTF start 365 and 
CTF start 375, see Supplementary Data, Table 
S1. The mutagenesis was performed on CTFwt 
mentioned above. For CTF start 375 D385A 
the same primers were used as for CTF start 
375 but the template was CTF D385A, which 
has also been described elsewhere (30). The 
CTF molecules were cloned into BamH1/Not1 
sites in the pcDNA5FRT/TO vector 
(Invitrogen). Introduction of the glycosylation 
acceptor sites on PS1wt and PS1∆exon 10, 
both in pcDNA5FRT/TO, were performed 
using the OptC primers (Supplementary Data, 
Table S1) according to Quick Change 
mutagenesis protocol (Stratagene). The APPwt 
in pcDNA3, used for generating a stable cell 
line, was cloned into the previously described 
pENTR2B vector (31) on NotI/EcoRV sites 
and then transferred to the pCAG-IRES-Puro 
vector using Gateway cloning technology 
(Invitrogen). The DNA sequence of all 
constructs was verified using the BigDye® 
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Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems). The reporter constructs: 
MH100, CMV-β-gal, C99-GVP and Notch∆E-
GVP used in the luciferase-based reporter gene 
assay have been described previously (32,33).  
Cell culture and transfection- Blastocyst-
derived embryonic stem cells deficient for PS1 
and PS2, BD8 cells (34), were cultured in ES 
medium; DMEM supplemented with 10% fetal 
calf serum, 1 mM sodium pyruvate, 0.1 mM β-
mercaptoethanol and non-essential amino acids 
(Invitrogen). Flp-In-BD8 cells, established 
elsewhere (26),  stably expressing APPwt in 
pcDNA3.1 (BD8:APP) were generated by 
transfection  following maintenance in media 
supplemented with puromycin (1 µg/ml) for 2 
weeks. Clonal picking and characterization of 
APP expression was preformed to avoid clonal 
variation. A clone with high APP expression 
was chosen for further use in these 
experiments. The same clone were also used 
for creating cell lines stably expressing the 
PS1wt- or PS1∆exon 10- pcDNA5-FRT/TO 
vectors, generated according to the Flp-In 
protocol (Invitrogen). Briefly, by co-
transfecting a vector containing the gene of 
interest and an FRT site together with a vector 
encoding the Flp recombinase this system 
targets the gene to a specific genomic site. 
Following transfection, cells were selected by 
supplementing the medium with hygromycin 
(750 µg/ml) for 2 weeks. The surviving cells 
were expanded and further analyzed for their 
PS1 expression  
BD8 cells stably expressing PS1 NTFwt 
(BD8:NTF) have been previously generated in 
our laboratory (35). The cDNA constructs 
were transiently transfected into the BD8, 
BD8:APP and BD8:NTF using the 
Lipofectamine2000 reagent (Invitrogen) 
according to the manufacturer’s instructions.  
Antibodies for immunoblottning- PS1-NTF 
(NT-1, a gift from Dr. Paul M. Mathews, 
Nathan Kline Institute) recognizing the C-
terminal loop region of PS1, NCT (N1660, 
Sigma-Aldrich) raised against C-terminal 
residues 693-709 of  Nicastrin, Pen-2 (3981 
ProSci Incorporated) raised against residues 
1-13 of Pen-2, Aph-1aL (O2C2, Covance) 
recognizing the residues 245-265 of Aph-1aL 
and β-actin (Abcam).  
SDS-PAGE and Western blot- Cells were lysed 
24-48 hours post transfection in Cell lysis 
buffert (10 mM Tris pH 8.1, 1 mM EDTA, 150 
mM NaCl and 0.65% Nonidet P-40) 
supplemented with Protease Inhibitor Cocktail 
(Roche). Protein levels were determined by the 
BCATM Protein Assay kit (PIERCE) and equal 
amount of protein in Laemmli sample buffer 
(SIGMA) were separated using NuPAGE BIS-
Tris pre-cast gradient 4-12% gel and MES 
buffer (Invitrogen). Proteins were transferred 
to a nitrocellulose membrane (BioRad) and 
blocked with 5% dry milk followed by 
incubation of primary antibody over night at 4 
°C. After applying the secondary horseradish 
peroxidise linked antibodies (1:2000, GE 
Healthcare) for one hour in room temperature 
the blots were developed with ECL solution, 
Immobilon™ Western Chemiluminescent HRP 
Substrate (Millipore) using Amersham 
HyperfilmTM ECL (GE Healthcare) or the 
CCD camera LAS-3000 (FUJIFILM Life 
Science). In the case of quantification, the 
respective bands were measured using ImageJ 
software (NIH).  
Co-immunoprecipitation- Co-immunoprecipi-
tation experiments were carried out 48 hours 
post transfection from BD8 cells grown in 10 
cm plates. Cells were harvested in PBS, 
pelleted and lysed by sonication in 200 µl co-
immunoprecipitation buffer containing: 50 mM 
Hepes pH 7.4, 150 mM NaCl, 2 mM EDTA, 
1% CHAPSO and Protease Inhibitor Cocktail 
(Roche). The samples were kept on ice, and all 
incubations were performed at 4 °C. The lysate 
were subjected to ultracentrifugation at 
100 000 x g for 20 min, followed by 
preclearing of the supernatant by 50 µl/ml 
lysate with a mixture of protein A and protein 
G sepharose (Amersham). Samples were then 
incubated with primary antibody diluted 1:250 
over night with end-over-end rotation. The 
Nicastrin antibody N1660 and the Aph-1aL 
antibody O2C2 were used as primary 
antibodies or purified rabbit IgG as a negative 
control. The following day, a mixture of 
protein A and protein G sepharose was added 
to the samples and incubated for an additional 
1 hour. Next, the precipitates were washed 
three times with co-immunoprecipitation 
buffer containing 0.5% CHAPSO and once in 
PBS. Laemmli sample buffer (SIGMA) was 
added and incubated at room temperature for 
30 min prior to SDS-PAGE and Western blot. 
The membranes were then analyzed with the 
NT1, and 3981 antibodies. 
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GCB pulldown- To analyze the presence of 
active γ-secretase complexes, BD8 cells stably 
expressing PS1wt- or PS1∆exon 10 were 
subjected to GCB pulldown. GCB is composed 
of the γ -secretase inhibitor L685,458 and a  
biotin group separated by a long cleavable 
hydrophilic linker. The GCB pulldown, its 
structure and characteristics have been 
described previously (36). Briefly, membrane 
preparations of the cells were dissolved in 
0.5% CHAPSO and protein levels were 
determined by the BCATM Protein Assay kit 
(PIERCE) before the GCB pulldown. The 
specificity of the pulldown was confirmed by 
the addition of excess amounts of competing 
non-biotinylated L685,458. The captured γ-
secretase components were eluted, subjected to 
SDS-PAGE and Western blot and analyzed 
with the NT1 antibody. 
Endoglycosidase H treatment- BD8 cells 
transiently transfected with PS1wt, PS1wt 
optC, PS1∆exon 10 or PS1∆exon 10 optC in 6-
well tissue culture plates were harvested 24 
hours post-transfection. The Endoglycosidase 
H treatment has been described elsewhere (37). 
Protein levels were determined by the BCATM 
Protein Assay kit (PIERCE) and next the 
samples were subjected to SDS-PAGE and 
Western blot and then analyzed with the NT1 
antibody. 
Determination of the endoproteolytic pattern 
of the PS1∆exon 10 molecule- The 
endoproteolysis pattern of the PS1∆exon 10 
molecule was analyzed from seven membranes 
by quantifying the intensity of the full-length, 
FL, and the NTF band of PS1wt and PS1∆exon 
10 in the CCD camera. Next, the ratio of 
NTF/FL were calculated and compared to the 
ratio for the PS1wt.  
Luciferase reporter gene assay- BD8 cells 
were transfected using a total amount of 1500 
ng DNA consisting of: 300 ng PS1wt/ 
PS1∆exon 10 or 300 ng of each NTFwt and 
truncated CTF, empty pcDNA5 vector was 
also added to adjust of difference in DNA 
amounts. Further, 300 ng MH100, 200 ng 
CMV-β-gal, 100 ng GFP and 300 ng C99-
GVP/Notch∆E-GVP were added. Cells were 
lysed 36 hours post transfection and then 
analyzed as previously described (33). To 
adjust for differences in transfection efficiency, 
the β -galactosidase activity of the cell lysate 
was determined. The luciferase activity was 
also normalized for protein expression using a 
PS1-NTF antibody (NT-1). Experiments were 
performed in triplicates and repeated 4-5 times. 
Quantification of secreted Aβ- A sandwich 
immunoassay using the Meso Scale Discovery 
Sector Imager 6000 was used to quantify 
secreted Aβ peptides in conditioned medium. 
All reagents were from Meso Scale Discovery, 
if not stated otherwise. BD8:APP were 
transfected with 800ng PS1wt/ PS1∆exon 10 
or 800ng of each NTFwt and truncated CTF, 
empty pcDNA5 vector was added to adjust for 
differences in DNA amounts, 200 ng CMV-β-
gal and 100 ng GFP. Next, cells were 
incubated in 240 µl of fresh ES medium 
containing either 1 µM L685,458 or vehicle 
(DMSO) for 36 hours before analysis of the 
conditioned medium. Multi-Array plates pre-
coated with either Triplex C-terminal specific 
anti-Aβ40/38/42 antibodies or 6E10 were 
blocked and washed according to 
manufacturer’s instructions. Media samples 
and Aβ peptide standards (Meso Scale 
Discovery and AnaSpec) as well as a 
ruthenylated- 6E10 or C-terminal specific anti-
Aβ42 (SULFO-TAG™) detection antibodies, 
or primary anti-Aβ40 and anti-Aβ39 antibodies 
(both from AstraZeneca), were added to the 
samples before incubation at 4°C over night. 
Next day, the 6E10 pre-coated plates with 
primary anti-Aβ40 or anti-Aβ39 antibodies 
were subjected to a secondary ruthenylated-
anti-rabbit (SULFO-TAG™) antibody. For 
total Aβ detection, samples were incubated 
over night and then subjected to ruthenylated- 
4G8 (SULFO-TAG™) at room temperature for 
2 hours, before all plates were washed. All 
antibodies were diluted in 1% blocking buffer. 
For detection, Meso Scale Discovery Read 
buffer was added and the light emission at 620 
nm was measured after electrochemical 
stimulation. The corresponding concentrations 
of Aβ peptides in the samples were calculated 
using the Aβ peptide standard curves. Next, the 
β-galactosidase activity of the cell lysate was 
determined, to adjust for differences in 
transfection efficiency. The secreted Aβ40 
peptide was also normalized for protein 
expression using a PS1-NTF antibody (NT-1). 
Experiments were performed in triplicates or 
duplicates and repeated 4-6 times. 
Cycloheximide treatment of cells- BD8 and 
BD8:NTF cells were transfected in one well of 
a 6 well tissue-culture plate with 500 ng CMV-
β-gal and 200 ng GFP as well as 2000 ng 
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PS1wt or PS1∆exon 10 for BD8 cells or 2000 
ng each of CTFwt or CTF start 375 for 
BD8:NTF. 6 hours post transfection, the cells 
were divided to 8 wells and incubated for 36 
hours. Transfected cells were exposed to 50 
µg/ml cycloheximide for 0, 0.5, 1, 2, 4, 8, 12 
and 16 hours and then lysed in 200 µl Whole 
cell extraction buffer (20 mM HEPES pH 7.8, 
0.42 M NaCl, 0.5% NP40, 25% glycerol, 0.2 
mM EDTA, 1.5 mM MgCl2, 1 mM DTT) 
supplemented with Protease Inhibitor Cocktail 
(Roche) for 30 min at 4 °C. Protein levels were 
determined by the BCATM Protein Assay kit 
(PIERCE) and equal amount of protein from 
the cell extracts from the T=0 time-point was 
analyzed for full-length PS1 and/or PS1 NTF 
expression by SDS-PAGE and 
immunoblottning using the NT1 antibody. β -
galactosidase measurements was done, as 
described above, to ensure equal transfection 
efficiency After quantifying the intensity with 
the CCD camera,  protein levels for the 
different constructs were correlated to the 
construct showing the lowest expression, i.e. 
PS1wt vs. PS1∆exon 10 and CTFwt vs. the 
CTF start 375. Proteins from various time 
points for each construct were separated by 
SDS-PAGE on 4-12% Bis-Tris gels and 
analyzed as above. The same blots were also 
stained with anti-β-actin antibody to ensure for 
equal amounts of loaded protein. The 
experiment was repeated three times. 
Statistics- All experiments in this paper were 
performed at least three times in duplicates or 
triplicates. The non-parametric Mann-Whitney 
U test by the STATISTICA 8 software from 
StatSoft was used for statistical analysis. 
 
RESULTS 
 
Metabolism and topology of PS1 lacking 
exon 10.  Although the large hydrophilic loop 
in PS1 has been suggested to be dispensable 
for γ-secretase activity (27,28) we wanted to 
further explore the altered Aβ generation 
observed in a knock-in mouse model lacking a 
big portion of this loop (29). To address this 
we have used cells deficient for PS1 and PS2 
(BD8), to nullify the influence from 
endogenous PS, thereby simplifying 
interpretation of results. We constructed a 
cDNA that encodes the human PS1 protein 
without the loop region (∆320-374), termed 
PS1∆exon 10 (Fig. 1A). Since the 
endoproteolytic site is still present in the 
construct (Met292) (38,39), we did not expect 
to disrupt this cleavage event. Indeed, a 30-
kDa PS1∆exon 10 derived NTF, which co-
migrated with NTF derived from full-length, 
FL, PS1wt was observed when these constructs 
were transfected into BD8 cells (Fig. 1B). As 
expected, the “full-length” PS1∆exon 10 also 
migrated faster on the gel compared to full-
length PS1wt due to the deletion of 55 amino 
acids a in the loop (Fig. 1B).  
To investigate if PS1∆exon 10 could 
form γ -secretase complexes we performed co-
immunoprecipitation studies under conditions 
preserving complex integrity. By using two 
different capture antibodies, we showed that 
the PS1∆exon 10 molecule interacted with 
nicastrin, Aph-1 and Pen-2 (Fig. 1C). In 
addition, by using GCB pulldown, we 
confirmed that an active site directed transition 
state analogue inhibitor of γ-secretase binds to 
the PS1-NTF of the PS1∆exon 10 molecule 
(Fig. 1D). This demonstrates that PS1∆exon 10 
can assemble into a bona fide authentic and 
active γ -secretase complex. However, we 
observed a tendency of decreased binding of 
PS1Δexon10 compared to PS1wt (15-70% 
reduction, three independent experiments) to 
the inhibitor (the ratio pulldown NTF/input 
NTF). This suggests a conformational change 
of the active site in the PS1Δexon 10 molecule. 
Interestingly, we noticed that lower 
levels of NTF were formed from PS1∆exon 10 
compared to PS1wt (Fig. 1B). We therefore 
compared the endoproteolytic pattern of 
PS1∆exon 10 to PS1wt. By quantifying the 
full-length, FL, and the NTF band of PS1wt 
and PS1∆exon 10 and calculating the ratio of 
NTF/FL, we demonstrated that endoproteolysis 
of the PS1∆exon 10 molecule was ten-fold 
decreased compared to PS1wt (Fig. 1E). To 
address if this endoproteolytic pattern was due 
to a transiently overexpressed system, we also 
generated stable BD8 cell lines expressing 
PS1wt and PS1Δexon 10, respectively, and 
observed the same endoproteolytic pattern 
(data not shown). Thus, the large cytoplasmic 
loop seems to affect the rate of endoproteolysis 
of the PS1 molecule. 
Next, we wanted to study the possibility 
that the removal of the loop had altered the 
topology of the PS1 molecule. Our group has 
previously shown that PS1 has nine TMDs 
(13), where the N-terminus is facing the 
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cytosol and the C-terminus is facing the lumen. 
In order to determine the topology for the 
PS1∆exon 10 molecule we introduced a 
glycosylation acceptor site (Asn-Ser-Thr) in 
the C-terminal end. Glycosylation patterns for 
the transiently expressed constructs in BD8 
cells were assessed by immunoblotting. The 
introduction of the glycosylation acceptor site 
resulted in a shift in migration for both the full-
length PS1wt and PS1∆exon 10 (Fig. 1E, lane 
4 & 8). Endoglycosidase H treatment reduced 
the size of the protein (Fig. 1F lane 5 & 9), 
confirming that the shift was caused by 
glycosylation and indicating that the C-
terminus in the PS1∆exon 10 molecule had a 
luminal/extracellular orientation. Thus, the 
exon 10 deletion did not appear to induce an 
aberrant topology of the molecule.  
The exon 10 coding region is vital for γ-
secretase complex assembly and the complexes 
formed remain stable. To address if the 
apparent lower levels of NTFwt produced from 
PS1∆exon 10 is due to impaired 
endoproteolysis or if it is a consequence of less 
stable γ -secretase complexes, we generated a 
PS1 CTF construct lacking exon 10, CTF start 
375 (Fig. 2A). When co-expressed with PS1 
NTFwt in BD8 cells, thus bypassing 
endoproteolysis, we observed lower levels of 
NTFwt in the presence of CTF start 375 than 
in the presence of CTFwt. We also observed a 
lower expression level of NTFwt when using 
BD8 cells stably expressing NTFwt, 
BD8:NTF, (Fig. 2B). To analyze the stability 
of the complexes, we treated BD8:NTF cells 
expressing CTFwt and CTF start 375 
molecules as well as BD8 cells expressing 
PS1∆exon 10 and PS1wt, with 50 µg/ml 
cycloheximide for different time points. We 
found that NTFwt co-expressed with CTF start 
375 had a comparable half-life with NTFwt co-
expressed with CTFwt, when monitoring 
between 1 hour to 16 hours (Fig. 2C). The 
same was observed for the PS1∆exon 10 
molecule, which half-time was comparable 
with the PS1wt (Fig. 2D). This indicates that 
the loop is important for complex formation, 
since we still observed lowered NTF levels 
even under conditions bypassing PS 
endoproteolysis. The complexes formed from 
PS1 molecules lacking the loop remain as 
stable as wild type complexes.  
 
PS1∆exon 10 affects Aβ formation but 
not AICD generation. Next, we wanted to 
assess the functional impact of PS1∆exon 10 
on AICD and Aβ production. The PS1∆exon 
10 molecule was transiently expressed in BD8 
cells and γ -secretase activity was determined 
by monitoring AICD generation through the 
use of a luciferase reporter gene assay (32,33). 
Expression of PS1∆exon 10 did not reduce 
AICD generation compared to PS1wt when 
normalizing for protein expression (Fig. 3A). 
This finding is not compatible with in vivo data 
from Deng et al., which indirectly showed a 
decreased AICD formation by demonstrating 
an accumulation of APP-CTF in the PS1∆exon 
10 knock-in mice (29). However, when we 
also monitored NICD production we also 
found an unperturbed processing with the 
PS1Δexon 10 molecule (Fig. 3A).  
Furthermore, we investigated the 
influence of PS1∆exon 10 on Aβ production 
by transfecting PS1wt or PS1∆exon 10 cDNA 
into BD8 cells stably expressing APPwt 
(BD8:APP). Sandwich immunoassay 
quantification revealed that the total Aβ 
production was strikingly impaired in cells 
transfected with PS1∆exon 10 compared to 
PS1wt (Fig. 3B). Importantly, the production 
of Aβ38, Aβ39 and Aβ40 was severely 
impaired, whereas the effect on Aβ42 
generation was affected to a much lesser extent 
(Fig. 3C). Importantly, we observed the same 
production of Aβ40 when normalizing for 
NTF expression, indicating that the result 
is not due to lower levels of PS1 (Fig. 3D). 
Thus, the PS1∆exon 10 protein seems to affect 
Aβ40 generation more than Aβ42, similar to 
many PS1 FAD mutations (22,23). This also 
resulted in a 4.4 fold increase in the 
Aβ42/Aβ40 ratio for PS1∆exon 10 compared 
to PS1wt (Fig. 3E). This suggests that the large 
hydrophilic loop of PS1 affects ε/S3-site and γ-
site cleavage differentially. 
APP processing is affected when the last 
ten amino acids in the loop are removed. To 
assay how γ-secretase activity is affected by 
the absence of the loop under conditions 
bypassing endoproteolysis, we examined the 
impact of the CTF start 375 molecules on APP 
processing. We have previously shown that co-
transfection of PS1 CTFwt and NTFwt can 
interact and restore γ -secretase activity in PS 
null cells (30). Using a luciferase reporter gene 
assay, we observed that co-expression of PS1 
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NTFwt and CTF start 375 had the same effect 
on AICD formation as CTFwt and the PS1 
lacking exon 10. Interestingly, the sandwich 
immunoassay also revealed a remarkably 
similar production pattern of different Aβ 
peptides as well as the total Aβ generation for 
the co-expressed NTFwt and CTF start 375 
compared to the PS1∆exon 10 molecule (Fig. 4 
c.f. Fig. 3).  
To narrow down the region in exon 10 
that is responsible for proper PS1 activity, we 
created an array of N-terminal truncated PS1 
CTF molecules (Fig. 5A). When γ-secretase 
activity was assayed for these different 
truncated CTFs (expressed together with 
NTFwt) an unchanged activity at the ε-site 
(monitored by AICD formation) was observed 
for all truncations when normalizing for 
protein expression (Fig. 5B). However, a 
gradual decline in activity at the γ-site was 
seen paralleling the extent of truncation (Fig. 
5C). The most dramatic shift in both activity 
and cleavage pattern could be seen between 
expressing CTF start 365 and CTF start 375 
(Fig. 5D). Strikingly, the formation of Aβ42 
was relatively unperturbed between the 
constructs, whereas expression of CTF start 
375 resulted in a drastic decrease in formation 
of the shorter Aβ variants (Aβ40, Aβ39, 
Aβ38). Taken together, these results suggest 
that the loop domain controls the extent of Aβ 
formation, without affecting AICD production, 
and that the last C-terminal ten amino acids in 
the PS1 loop seems to differentially affect 
production of shorter Aβ variants. 
 
DISCUSSION 
 
PS is the catalytic moiety of the γ -
secretase complex, which mediates both 
essential cell biological processes such as 
Notch receptor signaling, as well as cleavage 
of APP resulting in production of the AD-
related Aβ-peptide. Despite its critical role in 
normal biology and pathobiology, the 
enzymatic mechanism underlying γ -secretase-
mediated Notch and APP processing remains 
in large part elusive. To gain further insight 
into γ-secretase mediated catalysis, we have in 
this study focused on PS1. In particular, we 
concentrated our studies on the evolutionarily 
non-conserved hydrophilic loop, located 
between TMD6 and 7 in PS1, which has been 
suggested to be important for γ -secretase 
function. Our data show that this region plays a 
pivotal role for γ -secretase biology. First, the 
loop is required for efficient γ -secretase 
assembly and endoproteolysis. Second, it 
regulates γ -secretase activity differentially 
between the ε/S3-site and the γ-site. Third, the 
loop region is important for regulating Aβ 
production, where its absence causes a 
dramatic decrease in the formation of the 
shorter Aβ38, Aβ39 and Aβ40 isoforms and 
total Aβ released. Notably, the production of 
Aβ42 is only partially impaired under the same 
conditions. It is interesting to note that this 
effect on Aβ production resembles the Aβ 
phenotype of many FAD-linked PS1 mutants 
(22,23). Similar to the PS1∆exon 10 mutant, a 
total decrease in Aβ production, in 
combination with a less impaired Aβ42 
generation, results in an increased Aβ42/Aβ1-
X ratio for the FAD associated PS mutants. 
This Aβ-phenotype causes an enhanced 
amyloidosis in FAD as well as transgenic 
models harbouring FAD-linked PS. The FAD-
like Aβ phenotype of PS1∆exon 10 also 
translates to increased amyloidosis, as recently 
demonstrated by Deng et al in transgenic mice 
(29).  
The mechanism underlying FAD-linked 
production of different species (causing an 
increased Aβ42/ Aβ1-X ratio) is not known. 
One hypothesis, which has been raised, is that 
FAD-linked mutations give rise to a partial 
loss of function of the γ -secretase, which in 
turn causes a more severe effect on shorter Aβ 
peptides compared to the longer Aβ42 peptide. 
Our results are to some extent congruent with 
this hypothesis, since removal of the 
cytoplasmic loop causes a partial reduction in 
Aβ42, whereas the amount of the shorter 
secreted Aβ38, Aβ39 and Aβ40 peptides were 
decreased with 80% or more. Accordingly, our 
data would fit a partial loss of function model, 
except that the PS1Δexon 10 molecule is fully 
active at the ε/S3-site, which is not the case for 
most of PS FAD mutants. This suggests that 
PS1Δexon 10 γ -secretase processing is 
initiated by unperturbed ε -cleavage but 
gradually resulting in shorter peptides, 
especially beyond Aβ40. Several mechanisms 
could lead to a partial loss of γ -secretase 
processing. Our data show that the stability of 
the γ -secretase complex is not changed in the 
absence of the loop region, ruling out this 
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mechanism as responsible for the impaired γ -
secretase mediated APP processing.  
We have previously shown that it is 
possible to reconstitute γ -secretase activity in 
the absence of PS endoproteolysis, by 
expressing PS NTF and CTF encoding 
constructs in PS null cells (30). This 
experimental paradigm enables a powerful 
system to study different domains and amino 
acids in PS for different aspects of PS biology. 
By utilizing this system we could observe that 
partial deletions of the loop region, from the 
N-terminal end to only a few amino acids 
remaining of the C-terminal end of the loop 
region, cause a progressive loss of both Aβ38, 
Aβ39 and Aβ40 as well as of Aβ42 production, 
which is in agreement with a gradual loss of 
function. Interestingly however, when 
removing the last C-terminal amino acids of 
the loop, Aβ42 production is not further 
impaired, whereas the production of Aβ38-40 
is dramatically lowered. Thus, it appears that 
the C-terminal amino acids of exon 10 are 
more important for Aβ38-40 production than 
for Aβ42.  These data also implicate that the 
differential effect on Aβ42 versus shorter Aβ 
peptides could not solely be explained by a 
general loss of function, since we would then 
have expected a concomitant lowering in Aβ42 
and AICD upon removing the most C-terminal 
amino acids.  
We do not currently understand why this 
region has a differential effect on Aβ peptide 
production, but the primary structure may be 
important. This is supported by the observation 
that expression of full-length ∆exon 10 results 
in the same phenotype as expression of NTFwt 
and CTF start 375: endoproteolysis of ∆exon 
10 results in a CTF with an extension of 20 N-
terminal amino acids (residues 300-320; 
encoded by exon 9). Although the removal of 
∆exon 10 results in an Aβ phenotype similar to 
many FAD mutants, no FAD causing mutation 
has so far been identified in this region. 
Irrespective of the relationship between Aβ42 
and the shorter peptides, the present study and 
the data on FAD mutants suggest that Aβ42 
production in particular seems to be less 
sensitive to genetic modifications of the 
presenilin gene. Indeed, in efforts identifying 
amino acids critical for inhibition by γ -
secretase-directed small molecules, Basi and 
colleagues made a similar observation, i.e. that 
many artificial mutants cause a more severe 
loss of shorter Aβ variants than Aβ42 (40). 
Future studies are warranted to explain the 
differential sensitivity of PS mutations on 
Aβ42 production versus other shorter Aβ 
peptides. 
Since many studies have pointed out the 
importance of sustaining the Notch signaling 
pathway in adulthood (9-12), the differences in 
Notch S3-site/ APP ε-site and APP γ-site 
processing that we observe in the absence of 
the loop is of great interest. One reason for the 
different cleavage activity observed could be 
due to a structural change in the docking or the 
active site. The removal of the loop may 
induce an altered topography in these sites, 
leading to a weaker binding to the substrates. 
Indeed, Kornilova et al have shown that PS 
FAD mutations have reduced photolabeling by 
a transition-state analogue (41). Moreover, 
Berezovska and colleagues have published two 
reports that show the influence of both genetic 
and pharmacological manipulations, which 
increase the Aβ42/Aβ40 ratio, to be associated 
with a uniformal conformational change in the 
catalytic site of PS1 (42,43). Our data using a 
biotin-labeled transition-state analogue 
inhibitor of γ-secretase show a trend of less 
binding (15-70% reduction) of PS1∆exon 10-
NTF compared to PS1wt-NTF when 
normalizing for their corresponding input 
NTF’s. This implicates that the active site of 
PS1∆exon 10 has a more close conformation 
than the PS1 wt. It remains to be established 
whether the loop region is critical for the 
activity of γ-secretase modulators (GSM).  
Thus, the loop can be important for the 
positioning of the substrates but that the initial 
processing at the ε/S3- site is not affected, 
whereas a gradually decrease occurs in the 
processing towards shorter peptides.  
In conclusion, the data presented here 
suggest that the production of Aβ42 is distinct 
from Aβ38, Aβ39 and Aβ40, and that the 
integrity of the large hydrophilic loop between 
TMD 6 and 7 of PS1 is important for proper γ-
secretase complex assembly, PS1 
endoproteolysis and determination of Aβ 
peptide profiles. The large hydrophilic loop 
does not however affect the AICD or NICD 
production. This result is of importance, since 
avoiding Notch processing is a prerequisite 
when designing drugs that target the γ -
secretase complex in the treatment of AD.  
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FIGURE LEGENDS 
 
Fig. 1. PS1 lacking exon 10 shows impaired endoproteolysis but forms complexes with 
other γ -secretase subunits. (A) Schematic presentation of PS1wt and the PS1∆exon 10, 
lacking amino acids 320 to 374. Arrowhead depicts the endoproteolytic site. (B) Western blot 
analysis of lysates from BD8 cells expressing PS1wt and PS1∆exon 10 using a PS1-NTF 
antibody (NT-1). (C) Co-immunoprecipitation of BD8 lysats expressing PS1wt and 
PS1∆exon 10 using two different capture antibodies; N1660 (raised against Nicastrin) and 
O2C2 (raised against Aph-1aL). Detection was performed with PS1-NTF antibody (NT-1) 
and Pen-2 (3981), respectively. § indicate an unspecific band and # indicate the IgG band. (D) 
GCB pulldown of BD8 cells stably expressing PS1wt or PS1∆exon 10. Western blot were 
analyzed for NTF expression with a PS1-NTF antibody (NT-1) (E) Quantification of the 
endoproteolysed forms (NTF) versus full-length forms (FL) from seven Western blots with 
lysed BD8 cells expressing PS1wt and PS1∆exon 10. The Western blots were probed with a 
PS1-NTF antibody (NT-1) and quantified with a CCD camera. The ratio NTF/FL from PS1wt 
was set to 1. (F) EndoH treatment of BD8 cells expressing PS1wt, PS1wt optC, PS1∆exon 10 
and PS1∆exon 10 optC, using a PS1-NTF antibody (NT-1), shows that PS1∆exon 10 has a 
normal nine transmembrane topology. Error bars indicate the S.D., and statistical significance 
is calculated by the non-parametric Mann-Whitney U test. *, p <0.05; **, p <0.01; ***, p 
<0.001. 
 
Fig. 2. The exon 10 region is important for efficient γ-secretase complex formation but 
does not affect the stability of formed complexes. (A) Schematic presentation of the CTF 
construct lacking exon 10, CTF start 375. (B) Expression analysis of lysed BD8 or BD8:NTF 
cells transfected with PS1wt, PS1∆exon 10, CTFwt, CTF start 375 and empty vector, 
respectively, using a PS1-NTF antibody (NT-1). A β-actin antibody was used to ensure equal 
amounts of loaded protein. (C, D) BD8:NTF cells transfected with CTF wt, CTF start 375 and 
empty vector and BD8 cells expressing PS1wt and PS1∆exon 10, respectively, were treated 
with cycloheximide (50 µg/ml) for seven different time points between 0 hours and 16 hours. 
Lysates were analyzed for NTF expression with a PS1-NTF antibody (NT-1). A β-actin 
antibody was used to ensure equal amounts of loaded protein. 
 
Fig. 3. PS1 lacking exon 10 possesses a differential loss of function on AICD and Aβ 
formation. (A) Lysats from BD8 cells expressing PS1wt and PS1∆exon 10 were monitored 
with a luciferase reporter gene assay for AICD and NICD production, using transiently 
transfected C99-GVP/Notch∆E-GVP, MH100 and CMV-β-gal constructs. Luciferase activity 
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was normalized for protein expression (right panel) and transfection efficiency. PS1wt was set 
to 100% AICD formation. The right panel is a representative western blot from four 
independent experiments, using a PS1-NTF antibody (NT-1). (B) Sandwich immunoassay 
was used for detection of secreted total Aβ production using 4G8 and 6E10 antibodies. Total 
Aβ was set to 100% for PS1wt. (C) Detection of secreted Aβ38, Aβ39, Aβ40 and Aβ42 using 
6E10 or C-terminal specific Aβ40/38/42 antibodies as a capture antibody and Aβ39, Aβ40, 
Aβ42 and/ or 6E10 specific antibodies for detection. Levels of Aβ38, Aβ39, Aβ40 and Aβ42 
for PS1wt were set to 100%, respectively. # indicate that the peptide were below detection 
limit regarding the standard curve, but <10% of wt. (D) When secreted Aβ40 was normalized 
for protein expression (right panel), the same production was observed as in C. The right 
panel is a representative western blot from four independent experiments, using a PS1-NTF 
antibody (NT-1). (E) Aβ42/Aβ40 ratio of PS1wt and PS1∆exon 10. Error bars indicate the 
S.D., and statistical significance is calculated by the non-parametric Mann-Whitney U test. *, 
p <0.05; **, p <0.01; ***, p <0.001.  
 
Fig. 4. The exon 10 encoding region of PS1 has no effect on AICD production but a 
direct effect on Aβ generation. (A) Luciferase reporter gene assay monitoring AICD 
generation in BD8 cells expressing the CTFwt or CTF start 375 molecules together with 
NTFwt, C99-GVP, MH100 and CMV-β-gal constructs. Luciferase activity was normalized 
for transfection efficiency using a β-galactosidase assay and protein expression (right panel). 
NTFwt + CTFwt was set to 100% AICD formation. The right panel is a representative 
western blot from four independent experiments, using a PS1-NTF antibody (NT-1). (B) 
Sandwich immunoassay was used for detection of secreted total Aβ production using 4G8 and 
6E10 antibodies. Total Aβ was set to 100% for NTFwt + CTFwt. (C) Detection of secreted 
Aβ38, Aβ39, Aβ40 and Aβ42 using 6E10 or C-terminal specific Aβ40/38/42 antibodies as a 
capture antibody and Aβ39, Aβ40, Aβ42 and/ or 6E10 specific antibodies for detection. 
Levels of Aβ38, Aβ39, Aβ40 and Aβ42 for NTFwt + CTFwt were set to 100%, respectively. 
# indicate that the peptide were below detection limit regarding the standard curve, but <10% 
of wt. (D) When secreted Aβ40 was normalized for protein expression (right panel), the same 
production was observed as in C. The right panel is a representative western blot from four 
independent experiments, using a PS1-NTF antibody (NT-1). (E) Aβ42/Aβ40 ratio of CTFwt 
and CTF start 375 with NTFwt. Error bars indicate the S.D., and statistical significance is 
calculated by the non-parametric Mann-Whitney U test. *, p <0.05; **, p <0.01; ***, p 
<0.001. 
 
Fig. 5. The ten most C-terminal amino acids encoded by exon 10 are important for 
regulating the Aβ profile. (A) Schematic presentation of the various N-terminal truncated 
CTF molecules. (B) Luciferase reporter gene assay monitoring AICD generation in BD8 cells 
expressing all CTF molecules together with NTFwt, C99-GVP, MH100 and CMV-β-gal 
constructs. Luciferase activity was normalized for transfection efficiency using a β-
galactosidase assay and protein expression (lower panel). NTFwt + CTFwt was set to 100% 
AICD formation. The lower panel is a representative western blot from four independent 
experiments, using a PS1-NTF antibody (NT-1). (C) Sandwich immunoassay was used for 
detection of secreted total Aβ production using 4G8 and 6E10 antibodies. Total Aβ was set to 
100% for NTFwt + CTFwt. (D) Detection of secreted Aβ38, Aβ39, Aβ40 and Aβ42 using 
6E10 or C-terminal specific Aβ40/38/42 antibodies as a capture antibody and Aβ39, Aβ40, 
Aβ42 and/ or 6E10 specific antibodies for detection. Levels of Aβ38, Aβ39, Aβ40 and Aβ42 
for NTFwt + CTFwt were set to 100%, respectively. # indicate that the peptide were below 
detection limit regarding the standard curve, but <10% of wt.  (E) When secreted Aβ40 was 
normalized for protein expression (lower panel), the same production was observed as in D. 
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The lower panel is a representative western blot from four independent experiments, using a 
PS1-NTF antibody (NT-1). (F) Aβ42/Aβ40 ratio of all CTF molecules with NTFwt. Error 
bars indicate the S.D., and statistical significance is calculated by the non-parametric Mann-
Whitney U test. *, p <0.05; **, p <0.01; ***, p <0.001. 
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 Figure 1 
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Figure 2  
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Figure 3 
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Figure 4 
 
 
 at SM
AC Consortium
 - University of Zürich, on M
arch 14, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
 
 
 
18 
 
Figure 5 
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